Cilnidipine + Chlorthalidone
Drug Name:
Cilnidipine + Chlorthalidone
List Of Brands:
Indication Type Description:
Pharmacology/ Pharmacokinetics
Indication:
Stage I hypertension with CV risk
Adverse Reaction:
Dizziness, Flushing, Headache, hypotension, peripheral edema
Palipitations,
GI disturbances, Increased micturition frequency
Depression, cerebral or myocardial ischemia,
Transcient blindness,
Rahes, fever, dry mouth, thirst,
Weakness, restlessness, seizures,
Oliguria, Fatigue, muscle cramps,
Anorexia
Contra-Indications:
Cardiogenic shock. recent myocardial infarction or unstable angina,
Severe hepatic or renal impairment,
Addisons disease,
Pre-existing hypercalcaemia,
Asthma
Hypersensitivity
Pregnancy
Lctation
Dosages/ Overdosage Etc:
Stage I hypertension with CV risk
Dosage
Once daily
Pharmacology/ Pharmacokinetics:
Pharmacology-
Clinidine has potntial inhibitory action on both L-and n-ytpe voltage-dependent
calcium channelsand has been shown to dilate different efferent arterioles
as effectively as afferent arterioles.
It inhibits the release of H-noradrenaline from sympathetic nrve endings.
It relaxes human arteries through dual mechanisms- i.e. by calcium channel antagonism
and increasing production of niric oxide by enhancement of endothelial nitric oxide
synthase.
Cilnidipine has shown to exert antisympathetic, renoprotective, neuroprotctive and
cardioprotective action.
Rationale for Combination-
Available data confirms that that treatment with single antihypertensive agent fails to acheive
B.P. goals in upto 75% of patients. The B.P lowering efficacy of the combination of two
different drugs classes is approximately 5 times greater than doubling the dose of one
of the drug.
Thus, the initial management of stage I or stage stage II hypertension with combination
antihypertensive is considered to be more beneficial . Both CCB and diuretics stimulate
the renin-angio-tensin system to recompensate for the reduced pressure in the glomerular
afferent arteriolar and loss of sodium, respy.
This combination provides an additional BP reduction and thus is an acceptable
combination therapy in hypertension management. (CIMS- 123 Oct.2013)